2017
DOI: 10.3389/fphar.2017.00732
|View full text |Cite
|
Sign up to set email alerts
|

Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands?

Abstract: Natural killer (NK) cells are critical effectors of the immune system. NK cells recognize unhealthy cells by specific ligands [e.g., MHC- class I chain related protein A or B (MIC-A/B)] for further elimination by cytotoxicity. Paradoxically, cancer cells down-regulate MIC-A/B and evade NK cell’s anticancer activity. Recent data indicate that cellular-stress induces MIC-A/B, leading to enhanced sensitivity of cancer cells to NK cell-mediated cytotoxicity. In this Perspective article, we hypothesize that current… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 49 publications
0
1
0
Order By: Relevance
“…Vincristine and oxaliplatin themselves only mildly impair NK cell cytotoxicity (Markasz et al, 2007). Chemotherapeutic agents can also enhance NK cell function by down-regulation of inhibitory 'self ' ligands on the target cell surface (Fine et al, 2010); therefore the sensitivity of tumor or other target cells to NK cell cytotoxicity can be initiated by modulation of activating and inhibitory ligands (Quirk and Ganapathy-Kanniappan, 2017). Pre-treatment with the cytokine interleukin 2 (IL-2) increases the anti-tumor response rate to oxaliplatin particularly in patients with low blood lymphocyte counts (Lissoni et al, 2005) but there are currently no data available on how this immune modulation may impact on the neuropathic side effects of chemotherapy.…”
Section: Nk Cells In Chemically Induced Neuropathiesmentioning
confidence: 99%
“…Vincristine and oxaliplatin themselves only mildly impair NK cell cytotoxicity (Markasz et al, 2007). Chemotherapeutic agents can also enhance NK cell function by down-regulation of inhibitory 'self ' ligands on the target cell surface (Fine et al, 2010); therefore the sensitivity of tumor or other target cells to NK cell cytotoxicity can be initiated by modulation of activating and inhibitory ligands (Quirk and Ganapathy-Kanniappan, 2017). Pre-treatment with the cytokine interleukin 2 (IL-2) increases the anti-tumor response rate to oxaliplatin particularly in patients with low blood lymphocyte counts (Lissoni et al, 2005) but there are currently no data available on how this immune modulation may impact on the neuropathic side effects of chemotherapy.…”
Section: Nk Cells In Chemically Induced Neuropathiesmentioning
confidence: 99%